Among individuals from the United Kingdom with multiple sclerosis, autologous hematopoietic stem cell transplantation led to significant relapse suppression up to 4 years, according to a ...
Following a key product update, Raymond James analyst Michael W. Freeman remains bullish on Medexus Pharmaceuticals ...
MaaT Pharma Announces Positive Safety Interim Analysis from DSMB for Phase 2b Trial Evaluating MaaT033 for Patients Receiving ...
Adia Nutrition Inc. (OTC Pink: ADIA), a pioneering force in advanced stem cell therapies and nutritional wellness, is proud ...
StockNews.com initiated coverage on shares of Global Cord Blood (NYSE:CO – Free Report) in a research note issued to investors on Monday. The firm issued a strong-buy rating on the medical research ...
The real-world safety profile of tisagenlecleucel appears to be more favourable than that reported in the JULIET study, which led to its FDA approval.
About 65% of melanoma patients do not respond to immunotherapy. New work by the team of Prof. Max Mazzone (VIB-KU Leuven ...
News-Medical.Net on MSN11h
Blocking an enzyme to overcome immunotherapy resistance in melanoma patientsAbout 65% of melanoma patients do not respond to immunotherapy. New work by the team of Prof. Max Mazzone (VIB-KU Leuven ...
Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the European Commission (EC) has approved an indication extension of DARZALEX® (daratumumab) subcutaneous (SC) ...
About 65% of melanoma patients do not respond to immunotherapy. New work by the team of Prof. Max Mazzone (VIB-KU Leuven Center for Cancer Biology) discovered that an enzyme called HPGDS (expressed in ...
About 65% of melanoma patients do not respond to immunotherapy. New work by the team of Prof. Max Mazzone (VIB-KU Leuven Center ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback